Filing Flows › Solesence (SLSN) › Q2 2026 › vs Q2 2025
Solesence (SLSN) Q2 2026 vs Q2 2025 (year over year)
Solesence's revenue fell $5.0M (-25%) from $20.4M in Q2 2025 to $15.3M in Q2 2026. The biggest changes: Product −$4.9M (-24%); Advanced Materials −$87K (-68%); Product and Service, Other −$52K (-53%).
Solesence, Q2 2026: revenue $15.3M (-25% year over year), operating margin 0.8%, net loss $158K, operating cash flow $191K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumer Products | $14.2M | $17.5M | −$3.3M | -19% |
| Personal Care ingredients | $1.1M | $2.7M | −$1.6M | -60% |
| Product | $15.3M | $20.2M | −$4.9M | -24% |
| Product and Service, Other | $46K | $98K | −$52K | -53% |
| Advanced Materials | $41K | $128K | −$87K | -68% |
| Revenue | $15.3M | $20.4M | −$5.0M | -25% |
| Net loss | $158K | −$3.2M | $3.4M | — |
| Costs & expenses | $15.5M | $21.5M | −$6.0M | -28% |
| Operating costs | $15.2M | $17.9M | −$2.7M | -15% |
| Interest & other, net | $279K | −$1.1M | $1.4M | — |
| Cost of revenue | $10.6M | $13.9M | −$3.3M | -24% |
| Research & development | $947K | $955K | −$8K | -0.8% |
| SG&A | $3.7M | $3.0M | $668K | +22% |
| Operating cash sources | $402K | $345K | $57K | +17% |
| Depreciation & amortization | $323K | $225K | $98K | +44% |
| Share-based compensation | $79K | $120K | −$41K | -34% |
| Net loss absorbed | $158K | −$3.2M | $3.4M | — |
| Working capital & other | $53K | $4.2M | −$4.2M | -99% |
| Operating cash flow | $191K | −$654K | $845K | — |
Questions
How much did Solesence's revenue grow year over year in Q2 2026?
Solesence's revenue fell $5.0M (-25%) from $20.4M in Q2 2025 to $15.3M in Q2 2026.
What drove Solesence's revenue change in Q2 2026?
Product −$4.9M (-24%); Advanced Materials −$87K (-68%); Product and Service, Other −$52K (-53%).